Overview

Injectable Drug Delivery Market is poised to value over CAGR of over 11.3% during the forecast period 2022 to 2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Injectable Drug Delivery Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Injectable Drug Delivery Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Injectable Drug Delivery Market:
• Baxter International, Inc.
• Becton, Dickinson and Company
• Gerresheimer Ag
• Pfizer, Inc.
• Eli Lilly and Company
• Sandoz (A Division of Novartis Ag)
• Terumo Corporation
• Teva Pharmaceutical Industries Ltd.
• SHL Group
• Schott AG
• West Pharmaceutical Services, Inc.
• Insulet Corporation
• Elcam Medical
• Ypsomed AG
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Injectable Drug Delivery Market Segmentation:
By Type
• Devices
 o Conventional Injection Devices
   o By Material
     o Glass
     o Plastic
   o By Product
     o Fillable Syringes
     o Prefilled Syringes
   o By Usability
     o Reusable Injection Devices
     o Disposable Injection Devices
 o Self-Injection Devices
   o Needle-Free Injectors
     o By Product
       o Fillable Needle-Free Injectors
       o Prefilled Needle-Free Injectors
     o By Technology
       o Jet-Based Needle-Free Injectors
       o Spring-Based Needle-Free Injectors
       o Laser-Powered Needle-Free Injectors
       o Vibration-Based Needle-Free Injectors
     o By Usability
       o Reusable Needle-Free Injectors
       o Disposable Needle-Free Injectors
   o Autoinjectors
     o By Product
       o Fillable Autoinjectors
       o Prefilled Autoinjectors
     o By Technology
       o Automated Autoinjectors
       o Manual Autoinjectors
     o By Design
       o Standardized Autoinjectors
       o Customized Autoinjectors
     o By Usability
       o Reusable Autoinjectors
       o Disposable Autoinjectors
   o Pen Injectors
     o By Product
       o Single-Chambered Pen Injectors
       o Dual-Chambered Pen Injectors
     o By Design
       o Standard Pen Injectors
       o Customized Pen Injectors
     o By Usability
      o Reusable Pen Injectors
       o Disposable Pen Injectors
   o Wearable Injectors
   o Other Devices
• Formulations
 o Conventional Drug Delivery formulations
   o Solutions
   o Reconstituted/Lyophilized formulations
   o Suspensions
   o Emulsions
 o Novel Drug Delivery formulations
   o Colloidal Dispersions
     o Niosomes
     o Liposomes
     o Polymeric/Mixed Micelles
     o Nanoparticles
       o Solid-Lipid Nanoparticles
       o Nanosuspensions
       o Nanoemulsions
   o Microparticles
     o Microspheres
     o Microcapsules
 o Long-Acting Injection formulations

By Formulation Packaging
• Ampules
• Vials
• Cartridges
• Bottles

By Therapeutic Usage Pattern
• Auto-immune diseases
  o Rheumatoid Arthritis
  o Multiple Sclerosis (Ms)
  o Crohn’s Disease
  o Psoriasis
  o Other Autoimmune Diseases
• Hormonal Disorders
  o Diabetes
  o Anemia'
  o Reproductive Health Disease
  o Antithrombotic/Thrombolytic Therapy
  o Osteoporosis
  o Growth Hormone Deficiency (Ghd)
• Orphan Diseases
• Oncology
• Other Therapeutic Applications
  o Pain Management
  o Allergies
  o Aesthetic Treatment
  o Hepatitis C
  o Hemophilia

By Usage Pattern
• Curative Care
• Immunization
• Other Usage Pattern

By Site of Administration
• Skin
• Circulatory/Musculoskeletal
• Organs
• Central Nervous System

By Distribution Channel
• Hospitals
• Retail Pharmacy Stores

By Facility of Use
• Hospitals & Clinics
• Home Care Settings
• Other Facilities of Use

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Injectable Drug Delivery Market By Type, By Formulation Packaging, By Therapeutic Usage Pattern, By Usage Pattern,  By Site of Administration, By Distribution Channel, By Facility of Use and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Injectable Drug Delivery Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Injectable Drug Delivery Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Injectable Drug Delivery Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Injectable Drug Delivery Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Devices
       7.1.1. Conventional Injection Devices
              7.1.1.1. By Material
                         7.1.1.1.1. Glass
                         7.1.1.1.2. Plastic
              7.1.1.2. By Product
                         7.1.1.2.1. Fillable Syringes
                         7.1.1.2.2. Prefilled Syringes
              7.1.1.3. By Usability
                         7.1.1.3.1. Reusable Injection Devices
                         7.1.1.3.2. Disposable Injection Devices
       7.1.2. Self-Injection Devices
              7.1.2.1. Needle-Free Injectors
                       7.1.2.1.1. By Product
                                  7.1.2.1.1.1. Fillable Needle-Free Injectors
                                  7.1.2.1.1.2. Prefilled Needle-Free Injectors
                       7.1.2.1.2. By Technology
                                  7.1.2.1.2.1. Jet-Based Needle-Free Injectors
                                  7.1.2.1.2.2. Spring-Based Needle-Free Injectors
                                  7.1.2.1.2.3. Laser-Powered Needle-Free Injectors
                                  7.1.2.1.2.4. Vibration-Based Needle-Free Injectors
                       7.1.2.1.3. By Usability
                                  7.1.2.1.3.1. Reusable Needle-Free Injectors
                                  7.1.2.2.3.2. Disposable Needle-Free Injectors
              7.1.2.2. Autoinjectors
                       7.1.2.2.1. By Product
                                  7.1.2.2.1.1. Fillable Autoinjectors
                                  7.1.2.2.1.2. Prefilled Autoinjectors
                       7.1.2.2.2. By Technology
                                  7.1.2.2.2.1. Automated Autoinjectors
                                  7.1.2.2.2.2. Manual Autoinjectors
                       7.1.2.2.3. By Design
                                  7.1.2.2.3.1. Standardized Autoinjectors
                                  7.1.2.2.3.2. Customized Autoinjectors
                       7.1.2.2.4. By Usability
                                  7.1.2.2.4.1. Reusable Autoinjectors
                                  7.1.2.2.4.2. Disposable Autoinjectors
              7.1.2.3. Pen Injectors
                       7.1.2.3.1. By Product
                                  7.1.2.3.1.1. Single-Chambered Pen Injectors
                                  7.1.2.3.1.2. Dual-Chambered Pen Injectors
                       7.1.2.3.2. By Design
                                  7.1.2.3.2.1. Standard Pen Injectors
                                  7.1.2.3.2.2. SCustomized Pen Injectors
                       7.1.2.3.3. By Usability
                                  7.1.2.3.3.1. Reusable Pen Injectors
                                  7.1.2.3.3.2. Disposable Pen Injectors
              7.1.2.4. Wearable Injectors
              7.1.2.5. Other Devices
  7.2. Formulations
       7.2.1. Conventional Drug Delivery formulations
              7.2.1.1. Solutions
              7.2.1.2. Reconstituted/Lyophilized formulations
              7.2.1.3. Suspensions
              7.2.1.4. Emulsions
       7.2.2. Novel Drug Delivery formulations
              7.2.2.1. Colloidal Dispersions
                       7.2.2.1.1. Niosomes
                       7.2.2.1.2. Liposomes
                       7.2.2.1.3. Polymeric/Mixed Micelles
                       7.2.2.1.4. Nanoparticles
                                  7.2.2.1.4.1. Solid-Lipid Nanoparticles
                                  7.2.2.1.4.2. Nanoemulsions
              7.2.2.2. Microparticles
                       7.2.2.2.1. Microspheres
                       7.2.2.2.2. Microcapsules
       7.2.3. Long-Acting Injection formulations

8. Global Injectable Drug Delivery Market, By Formulation Packaging Historical Analysis and Forecast 2022-2028 (USD Million)
  8.1. Ampules
  8.2. Vials
  8.3. Cartridges
  8.4. Bottles

9. Global Injectable Drug Delivery Market, By Therapeutic Usage Pattern Historical Analysis and Forecast 2022-2028 (USD Million)
  9.1. Auto-immune diseases
       9.1.1. Rheumatoid Arthritis
       9.1.2. Multiple Sclerosis (Ms)
       9.1.3. Crohn’s Disease
       9.1.4. Psoriasis
       9.1.5. Other Autoimmune Diseases
  9.2. Hormonal Disorders
       9.2.1. Diabetes
       9.2.2. Anemia'
       9.2.3. Reproductive Health Disease
       9.2.4. Antithrombotic/Thrombolytic Therapy
       9.2.5. Osteoporosis
       9.2.6. Growth Hormone Deficiency (Ghd)
  9.3. Orphan Diseases
  9.4. Oncology
  9.5. Other Therapeutic Applications
       9.5.1. Pain Management
       9.5.2. Allergies
       9.5.3. Aesthetic Treatment
       9.5.4. Hepatitis C
       9.5.5. Hemophilia

10. Global Injectable Drug Delivery Market, By Usage Pattern Historical Analysis and Forecast 2022-2028 (USD Million)
  10.1. Curative Care
  10.2. Immunization
  10.3. Other Usage Pattern

11. Global Injectable Drug Delivery Market, By Site of Administration Historical Analysis and Forecast 2022-2028 (USD Million)
  11.1. Skin
  11.2. Circulatory/Musculoskeletal
  11.3. Organs
  11.4. Central Nervous System

12. Global Injectable Drug Delivery Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)
  12.1. Hospitals
  12.2. Retail Pharmacy Stores

13. Global Injectable Drug Delivery Market, By By Facility of Use Historical Analysis and Forecast 2022-2028 (USD Million)
   13.1. Hospitals & Clinics
   13.2. Home Care Settings
   13.3. Other Facilities of Use

14. North America Injectable Drug Delivery Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  14.1. Introduction
  14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       14.2.1. U.S.A
       14.2.2. Canada
       14.2.3. Mexico
  14.3. Market Size (USD Million) Forecast for North America 2022-2028

15. Latin America Injectable Drug Delivery Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   15.1. Introduction
   15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         15.2.1. Brazil
         15.2.2. Venezuela
         15.2.3. Argentina
         15.2.4. Rest of Latin America
   15.3. Market Size (USD Million) Forecast for Latin America 2022-2028

16. Europe Injectable Drug Delivery Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   16.1. Introduction
   16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         16.2.1. Germany
         16.2.2. U.K        
         16.2.3. France
         16.2.4. Italy
         16.2.5. Spain
         16.2.6. Russia
         16.2.7. Poland
         16.2.8. Rest of Europe
   16.3. Market Size (USD Million) Forecast for Europe 2022-2028

17. Asia Pacific Injectable Drug Delivery Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   17.1. Introduction
   17.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         17.2.1. Japan
         17.2.2. China
         17.2.3. India
         17.2.4. Australia and New Zealand
         17.2.5. ASEAN
         17.2.6. Rest of Asia Pacific
   17.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

18. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   18.1. Introduction
   18.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         18.2.1. GCC
         18.2.2. Israel
         18.2.3. South Africa
         18.2.4. Rest of MEA
   18.3. Market Size (USD Million) Forecast for MEA 2022-2028

19. Market Share Analysis and Competitive Landscape  
   19.1. Global Landscape - Key Players, Revenue and Presence
   19.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   19.3. Global Emerging Companies
   19.4.  North America - Market Share Analysis and Key Regional Players
   19.5.  Europe - Market Share Analysis and Key Regional Players
   19.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   19.7.  Global Key Player - Growth Matrix

20. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   20.1. Baxter International, Inc.
         20.1.1. Company Overview
         20.1.2. Product Portfolio
         20.1.3. SWOT Analysis
         20.1.4. Financial Overview
         20.1.5. Strategic Overview
   20.2. Becton, Dickinson and Company
         20.2.1. Company Overview
         20.2.2. Product Portfolio
         20.2.3. SWOT Analysis
         20.2.4. Financial Overview
         20.2.5. Strategic Overview
   20.3. Gerresheimer Ag
         20.3.1. Company Overview
         20.3.2. Product Portfolio
         20.3.3. SWOT Analysis
         20.3.4. Financial Overview
         20.3.5. Strategic Overview
   20.4. Pfizer, Inc.
         20.4.1. Company Overview
         20.4.2. Product Portfolio
         20.4.3. SWOT Analysis
         20.4.4. Financial Overview
         20.4.5. Strategic Overview
   20.5. Eli Lilly and Company
         20.5.1. Company Overview
         20.5.2. Product Portfolio
         20.5.3. SWOT Analysis
         20.5.4. Financial Overview
         20.5.5. Strategic Overview          
   20.6. Sandoz (A Division of Novartis Ag)
         20.6.1. Company Overview
         20.6.2. Product Portfolio
         20.6.3. SWOT Analysis
         20.6.4. Financial Overview
         20.6.5. Strategic Overview      
   20.7. Terumo Corporation
         20.7.1. Company Overview
         20.7.2. Product Portfolio
         20.7.3. SWOT Analysis
         20.7.4. Financial Overview
         20.7.5. Strategic Overview
   20.8. Teva Pharmaceutical Industries Ltd.
         20.8.1. Company Overview
         20.8.2. Product Portfolio
         20.8.3. SWOT Analysis
         20.8.4. Financial Overview
         20.8.5. Strategic Overview
   20.9. SHL Group
         20.9.1. Company Overview
         20.9.2. Product Portfolio
         20.9.3. SWOT Analysis
         20.9.4. Financial Overview
         20.9.5. Strategic Overview
   20.10. Schott AG
         20.10.1. Company Overview
         20.10.2. Product Portfolio
         20.10.3. SWOT Analysis
         20.10.4. Financial Overview
         20.10.5. Strategic Overview
   20.11.West Pharmaceutical Services, Inc.
         20.11.1. Company Overview
         20.11.2. Product Portfolio
         20.11.3. SWOT Analysis
         20.11.4. Financial Overview
         20.11.5. Strategic Overview
   20.12.Insulet Corporation
         20.12.1. Company Overview
         20.12.2. Product Portfolio
         20.12.3. SWOT Analysis
         20.12.4. Financial Overview
         20.12.5. Strategic Overview
   20.13.Elcam Medical
         20.13.1. Company Overview
         20.13.2. Product Portfolio
         20.13.3. SWOT Analysis
         20.13.4. Financial Overview
         20.13.5. Strategic Overview
   20.14.Ypsomed AG
         20.14.1. Company Overview
         20.14.2. Product Portfolio
         20.14.3. SWOT Analysis
         20.14.4. Financial Overview
         20.14.5. Strategic Overview

21. Pre and Post COVID-19 Impact
   21.1. Positive influence on the healthcare industry
   21.2. The financial disruption of the manufacturing sector
   21.3. Impact of COVID-19 on emerging companies
   21.4. Significant mandates in the healthcare regulations initiated by administrations
   21.5. The overall economic slowdown of the developing and developed nations

22. FutureWise SME Key Takeaway Points for Client

Tables

Figures